Last reviewed · How we verify

aloevera juice

The Oxford Dental College, Hospital and Research Center, Bangalore, India · Phase 3 active Small molecule Under review

aloevera juice is a Small molecule drug developed by The Oxford Dental College, Hospital and Research Center, Bangalore, India. It is currently in Phase 3 development for Oral mucositis prevention and treatment.

Aloevera juice has anti-inflammatory and antioxidant properties that may help soothe and protect oral tissues.

Aloe vera juice has been studied as a potential treatment for Oral Submucous Fibrosis, a condition that has been the subject of a completed clinical trial. The exact mechanism by which aloe vera juice may exert its effects is currently unknown.

Likelihood of approval
58.3% vs 58.3% industry baseline
If approved by FDA: likely 2028–2030
Steps remaining: NDA/BLA submission
Confidence: High
Why this estimate
  • Baseline phase 3 → approval rate +58.3pp
    Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2028–2030
EMA EU 2029–2031 +0.7 yr
MHRA GB 2029–2031 +0.7 yr
Health Canada CA 2029–2032 +0.9 yr
TGA AU 2029–2032 +1.2 yr
PMDA JP 2029–2032 +1.5 yr
NMPA CN 2030–2033 +2.3 yr
MFDS KR 2029–2032 +1.4 yr
CDSCO IN 2029–2033 +1.8 yr
ANVISA BR 2030–2033 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic namealoevera juice
SponsorThe Oxford Dental College, Hospital and Research Center, Bangalore, India
ModalitySmall molecule
Therapeutic areaDental
PhasePhase 3

Mechanism of action

The exact molecular targets of aloevera juice are not well understood, but its anti-inflammatory and antioxidant effects are thought to be mediated by various bioactive compounds, including vitamins, minerals, and polyphenols. These compounds may help reduce inflammation and oxidative stress in the oral cavity, promoting healing and tissue protection.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about aloevera juice

What is aloevera juice?

aloevera juice is a Small molecule drug developed by The Oxford Dental College, Hospital and Research Center, Bangalore, India, indicated for Oral mucositis prevention and treatment.

How does aloevera juice work?

Aloevera juice has anti-inflammatory and antioxidant properties that may help soothe and protect oral tissues.

What is aloevera juice used for?

aloevera juice is indicated for Oral mucositis prevention and treatment.

Who makes aloevera juice?

aloevera juice is developed by The Oxford Dental College, Hospital and Research Center, Bangalore, India (see full The Oxford Dental College, Hospital and Research Center, Bangalore, India pipeline at /company/the-oxford-dental-college-hospital-and-research-center-bangalore-india).

What development phase is aloevera juice in?

aloevera juice is in Phase 3.

What are the side effects of aloevera juice?

Common side effects of aloevera juice include Gastrointestinal upset.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing